Translational Value of the Transdermal Administration of Bergamot Essential Oil and of Its Fractions.
clinical translation
decolored phytocomplex
deterpenated phytocomplex
essential oil of bergamot
formalin test
limonene
linalool
linalyl acetate
pain
transdermal route
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
07 May 2022
07 May 2022
Historique:
received:
09
04
2022
revised:
01
05
2022
accepted:
05
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
The essential oil of bergamot (BEO) has consistently proven antinociceptive and antiallodynic properties. Accordingly, the analgesic efficacy of the decolored essential oil (DEC), with higher levels of limonene, and the deterpenated (DET) fraction, with higher levels of linalool and linalyl acetate, was investigated using a formalin test after inhalation. The present study was aimed at characterizing the effects of BEO, its components with the highest pharmacological activity (represented by linalool, limonene, and linalyl acetate), and its DEC and DET fractions on the formalin test after transdermal administration relevant to clinical translation through topical application. To this aim, the schedule of intervention involved administration immediately after formalin injection or as a 5 min pretreatment followed by washout in ddY-strain mice. This study demonstrates, for the first time, the significant analgesic effect of all three constituents in the first and second phases, accounting for the efficacy of the essential oil in the formalin test. While all fractions revealed equal activity toward the phytocomplex in the early phase, the reduction in time of licking/biting during the late phase was more markedly induced by DEC. Moreover, pretreatment with BEO and its fractions followed by washout did not produce a significant reduction in licking/biting time in both phases of formalin-induced nociceptive response.
Identifiants
pubmed: 35631592
pii: pharmaceutics14051006
doi: 10.3390/pharmaceutics14051006
pmc: PMC9143031
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ingegno: POR Calabria FESR 2014/2020 - Azione 1 1 5 - Sostegno all'Avanzamento tecnologico delle Imprese Attraverso il Finanziamento di Linee Pilota e Azioni di Validazione Precoce di Prodotti e di Dimostrazione su Larga Scala (DDG N. 12814 DEL 17/10/2019
ID : Ingegno: POR Calabria FESR 2014/2020 - Azione 1 1 5 - Sostegno all'Avanzamento tecnologico delle Imprese Attraverso il Finanziamento di Linee Pilota e Azioni di Validazione Precoce di Prodotti e di Dimostrazione su Larga Scala (DDG N. 12814 DEL 17/10/2019
Références
Curr Neuropharmacol. 2020;18(1):34-50
pubmed: 31210112
Pain Manag. 2019 Sep;9(5):431-433
pubmed: 31452439
Pharmaceutics. 2021 Mar 12;13(3):
pubmed: 33809385
Pharmaceuticals (Basel). 2022 Feb 04;15(2):
pubmed: 35215311
Pain Res Treat. 2016;2016:8158693
pubmed: 28070420
Phytother Res. 2021 Oct;35(10):5333-5338
pubmed: 34435395
Funct Neurol. 2017 Oct/Dec;22(4):229-230
pubmed: 29306360
Sci Rep. 2019 Sep 23;9(1):13678
pubmed: 31548590
Front Pharmacol. 2021 Mar 01;12:640128
pubmed: 33732159
Neuropsychopharmacology. 2008 Sep;33(10):2341-51
pubmed: 18075491
Pharmacol Biochem Behav. 2011 Jan;97(3):436-43
pubmed: 20932858
PLoS One. 2017 Jan 26;12(1):e0170825
pubmed: 28125677
Mol Psychiatry. 2021 Aug;26(8):4085-4095
pubmed: 31732715
Front Pharmacol. 2020 Aug 21;11:1310
pubmed: 32973528
Int J Mol Sci. 2020 Feb 25;21(5):
pubmed: 32106479
Stroke. 2004 May;35(5):1203-8
pubmed: 15060322
J Educ Eval Health Prof. 2021;18:17
pubmed: 34325496
J Alzheimers Dis. 2017;56(2):707-716
pubmed: 28035931
Pharmacol Ther. 2022 Mar 16;237:108171
pubmed: 35304223
Front Pharmacol. 2020 Nov 27;11:587050
pubmed: 33424596
Clin Transl Sci. 2022 Jun;15(6):1472-1481
pubmed: 35244984
JAMA. 2005 Oct 19;294(15):1934-43
pubmed: 16234500
Int J Mol Sci. 2020 Apr 09;21(7):
pubmed: 32283606
Mol Pain. 2015 Feb 02;11:3
pubmed: 25645145
Food Chem. 2022 Aug 15;385:132659
pubmed: 35279498
Pain. 1988 Apr;33(1):11-23
pubmed: 2454440
BMJ. 2011 Jul 15;343:d4065
pubmed: 21765198
Molecules. 2015 Dec 23;21(1):E20
pubmed: 26703556
Life (Basel). 2020 Jul 04;10(7):
pubmed: 32635538
Pharmacol Res. 2007 Apr;55(4):255-62
pubmed: 17196823
BMJ. 2000 Oct 21;321(7267):992-3
pubmed: 11039965
Age Ageing. 2011 Nov;40(6):752-5
pubmed: 21937515
Front Pharmacol. 2020 May 08;11:663
pubmed: 32457634
Pharmaceutics. 2022 Jan 28;14(2):
pubmed: 35214045
Neuropsychopharmacology. 2015 Jan;40(1):254-5
pubmed: 25482181
Fitoterapia. 2018 Sep;129:20-24
pubmed: 29906556
Evid Based Complement Alternat Med. 2013;2013:927419
pubmed: 24454517
Eur J Clin Pharmacol. 2021 Feb;77(2):241-249
pubmed: 32935181
Neurosci Biobehav Rev. 2001 May;25(3):235-60
pubmed: 11378179
Pharmacol Biochem Behav. 2013 Feb;103(4):735-41
pubmed: 23159543
Curr Opin Pharmacol. 2021 Dec;61:69-76
pubmed: 34634603
Scand J Pain. 2017 Dec 29;4(2):58-62
pubmed: 29913900
BMC Med Res Methodol. 2014 Mar 26;14:43
pubmed: 24667063
Biochem Biophys Res Commun. 2020 Dec 17;533(4):764-769
pubmed: 32988589
Clin Interv Aging. 2013;8:1471-82
pubmed: 24204133
Front Neurol. 2020 Aug 26;11:890
pubmed: 32982921
Neural Regen Res. 2018 Sep;13(9):1619-1621
pubmed: 30127123
Neural Regen Res. 2020 Jul;15(7):1340-1343
pubmed: 31960822
J Pharm Biomed Anal. 2000 Dec;24(1):147-54
pubmed: 11108548
Clin Pharmacol Ther. 2009 Apr;85(4):431-3
pubmed: 19225449
Drugs Today (Barc). 2019 Nov;55(11):695-703
pubmed: 31840684
Br J Dermatol. 1977 May;96(5):475-82
pubmed: 871382
Molecules. 2017 Apr 11;22(4):
pubmed: 28398260